Conclusion of Evaluation with Stingray
Summary by AI BETAClose X
2 June 2026
ValiRx PLC
("ValiRx" or the "Company")
Conclusion of Evaluation with Stingray
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health provides the following update at the conclusion of the Evaluation Agreement with Stingray Bio Limited ("Stingray") announced on 5 August 2025.
Under the terms of the Evaluation Agreement with Stingray, ValiRx carried out in-silico lead optimisation of potency and target selectivity. Despite some interesting in-silico results, it was concluded the technology had not met the strict criteria for the Company to exercise its option to license the technology on pre-agreed terms.
Under the terms of the Evaluation Agreement, the jointly owned results will return to Stingray and, if Stingray secures alternative investment within 12 months of the Evaluation Agreement's completion, ValiRx will be entitled to a cash payment of 1.5x its total investment (estimated at approximately £50,000, including outsourced work and internal resources).
Mark Eccleston, CEO of ValiRx commented "We have completed this second evaluation phase of the Stingray assets ahead of schedule and well within budget. This phase focussed on in-silico lead optimisation following the initial evaluations of lead assets by Inaphaea and would require significant further lead optimisation and development to get to the candidate stage so we have elected not to proceed as we focus our resources on later stage assets.
This was the first of our new style, hybrid approach to evaluation and development programmes and so, whilst we are not progressing with the asset ourselves, the evaluation results will be assigned back to Stingray and we will retain some upside if it is commercialised in the next 12 months."
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/egGpbe
|
|
ValiRx plc
Dr Mark Eccleston, CEO
|
Tel: +44 115 784 0026 Mark.Eccleston@valirx.com
|
|
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
Jocelyn Braithwaite
|
+44 (0) 115 646 5491 www.vformation..co.uk
jocelyn@vformation.co.uk |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 6 minutes ago Personal Group Holdings
- 9 minutes ago Grainger
- 37 minutes ago Helios Underwriting
- 58 minutes ago SSE
- 2 hours ago Judges Scientific